SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2023
Paris, April 11, 2023 – SparingVision (“the Company”), a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces
announces today that it has been selected for three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting to be held from 23-27 April.
Poster Presentation: Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies
Date and Time: 23 April, 12:00 – 2:00 PM, Poster #773 – C0374
Presenter: Anne-Sophie Gautron, PhD
Session Title: Gene therapy and gene editing for ocular disorders
Session Number: 140
Poster Presentation: Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of rod-cone dystrophies (RCD)
Date and Time: 25 April, 8:45 AM – 10:45 AM, Poster #2591 – B0304
Presenter: Melanie Marie, PhD
Session Title: Retina/RPE: New drugs, mechanisms of action and toxicity
Session Number: 320
Poster Presentation: Mobility and postural testing in patients with rod-cone dystrophy enrolled in the prospective natural history study PHENOROD2
Date and Time: 26 April, 2:15 – 4:15 PM, Poster #4644 – C0109
Presenter: Mylène Poujade
Session Title: Retinitis pigmentosa
Session Number: 450
**ENDS**